

# ESMO PRECEPTORSHIP PROGRAMME

## PROSTATE CANCER

Multidisciplinary management, standards of care,  
therapeutic targets and future perspectives

Singapore  
9-10 December 2024

### CO-CHAIRS

Karim Fizazi, France  
Ravindran Kanesvaran, Singapore

### SPEAKERS

Hakan Aydin, Singapore  
Arun Azad, Australia  
Silke Gillessen, Switzerland  
Winnie Lam, Singapore  
Marniza Saad, Malaysia  
Jeremy Y. C. Teoh, Hong Kong SAR, China  
Thomas Zilli, Switzerland

## LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

## Monday, 9 December 2024

09:00-09:10 10'	Opening and welcome	
10'	Welcome from ESMO - Objectives and scientific introduction	Karim Fizazi, FR Ravindran Kanesvaran, SG
09:10-10:45 95'	<b>SESSION 1</b> Screening, diagnosis, staging and localised prostate cancer	<b>Chairs:</b> Hakan Aydin, SG Jeremy Y. C. Teoh, HK SAR, CN
20'	PSA screening, diagnosis and staging	Jeremy Y. C. Teoh, HK SAR, CN
15'	Pathological diagnosis for the clinician (including variants of PCa)	Hakan Aydin, SG
15'	Treatment of localised prostate cancer according to risk category	Jeremy Y. C. Teoh, HK SAR, CN
15'	Radiotherapeutic approaches for localised prostate cancer	Thomas Zilli, CH
15'	Q&A	All
15'	Participants Clinical Case discussion (1x15')	Faculty
10:45-11:15	Coffee break	

<b>11:15-12:40</b> 85'	<b>SESSION 2</b> <b>Biochemical relapse</b>	<b>Chairs:</b> <b>Jeremy Y. C. Teoh, HK SAR, CN</b> <b>Thomas Zilli, CH</b>
15'	Biochemical relapse: Definition and diagnostic algorithm	Jeremy Y. C. Teoh, HK SAR, CN
20'	Rising PSA after radical local treatment: Prognosis, indications for salvage local treatments, salvage vs adjuvant treatments	Thomas Zilli, CH
20'	Use of early vs deferred systemic treatments in high-risk localized CaP and biochemical failures	Karim Fizazi, FR
15'	Q&A	All
15'	Participants Clinical Case discussion (1x15')	Faculty
<b>12:40-13:40</b>	<b>Lunch</b>	
<b>13:40-15:20</b> 100'	<b>SESSION 3</b> <b>Systemic treatment options and molecular characterisation</b>	<b>Chairs:</b> <b>Ravindran Kanesvaran, SG</b> <b>Marniza Saad, MY</b>
20'	ADT and other hormonal treatments, mechanisms of action, main efficacy results and toxicities	Silke Gillessen, CH
20'	Chemotherapy (taxanes and platins) and Radium-223, mechanism of action, main efficacy results in Castration-Resistant Prostate Cancer (CRPC) and toxicities	Ravindran Kanesvaran, SG
15'	Bone health agents, mechanism of action, efficacy and toxicities	Marniza Saad, MY
15'	Molecular characterisation: Germline and somatic testing	Arun Azad, AU
15'	Q&A	All
15'	Participants Clinical Case discussion (1x15')	Faculty
<b>15:20-15:50</b>	<b>Coffee break</b>	
<b>15:50-17:20</b> 90'	<b>SESSION 4</b> <b>Castration-sensitive metastatic prostate cancer</b>	<b>Chairs:</b> <b>Karim Fizazi, FR</b> <b>Silke Gillessen, CH</b>
20'	Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	Silke Gillessen, CH
15'	Triplet and quadruplet options (mCSPC)	Karim Fizazi, FR
10'	Monitoring of mCSPC	Marniza Saad, MY
15'	Oligo-metastatic disease: What treatment?	Thomas Zilli, CH
15'	Q&A	All
15'	Participants Clinical Case discussion (1x15')	Faculty
<b>19:00</b>	<b>Networking Dinner</b>	

## Tuesday, 10 December 2024

<b>09:00-10:45</b> 105'	<b>SESSION 5</b> Non metastatic and metastatic castration-resistant disease	<b>Chairs:</b> Arun Azad, AU Winnie Lam, SG
20'	Non metastatic CRPC: Current treatment	Arun Azad, AU
20'	Metastatic CRPC: Current treatment	Silke Gillessen, CH
20'	PSMA-based therapies	Winnie Lam, SG
15'	Q&A	All
30'	Participants Clinical Case discussion (2x15')	Faculty
<b>10:45-11:15</b>	<b>Coffee break</b>	
<b>11:15-12:20</b> 65'	<b>SESSION 6</b> Metastatic castration-resistant disease	<b>Chairs:</b> Karim Fizazi, FR Silke Gillessen, CH
15'	Treatment in frail patients with mCRPC	Ravindran Kanesvaran, SG
20'	Experimental treatments for mCRPC	Karim Fizazi, FR
15'	Q&A	All
15'	Participants Clinical Case discussion (1x15')	Faculty
<b>12:20-12:30</b> 10'	<b>Conclusion and farewell</b>	<b>Karim Fizazi, FR</b> <b>Ravindran Kanesvaran, SG</b>
<b>12:30-13:30</b>	<b>Lunch</b>	

**Note:** Each 15-minute slot for clinical case discussion includes a 7' case presentation and a 8' Q&A / panel discussion